Drug Profile
Retronectin-induced T cell therapy - Takara Bio
Alternative Names: Cancer immunity reconstruction therapy; Cell-based cancer immunotherapyLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Takara Bio
- Developer Kyoto Prefectural University of Medicine; Takara Bio; Tianjin Medical University Cancer Institute and Hospital
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Gastrointestinal cancer; Liver cancer; Lung cancer; Pancreatic cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Late-stage disease, Second-line therapy or greater) in Japan (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Liver-cancer(Late-stage disease, Second-line therapy or greater) in Japan (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Lung-cancer(Late-stage disease, Second-line therapy or greater) in Japan (IV, Infusion)